T-cell non-Hodgkin lymphoma
MONDO:0015760A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003
Also known as: T cell lymphoma, T-cell NHL, T-cell and NK-cell non-Hodgkin lymphoma, T-cell and NK-cell non-Hodgkin's lymphoma, T-cell lymphoma, T-cell non-Hodgkin lymphoma, T-cell non-Hodgkin's lymphoma, non-Hodgkin's T-cell lymphoma
2312 clinical trials for this condition and its sub-types, 98 tagged with T-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of T-cell non-Hodgkin lymphoma
-
Mature T-cell and NK-cell non-Hodgkin lymphoma 150 trials · 240 incl. sub-types
8 sub-types
- Anaplastic large cell lymphoma 66 trials · 89 incl. sub-types Sub-types →
- Angioimmunoblastic T-cell lymphoma 58 trials
- T-cell large granular lymphocyte leukemia 18 trials
- T-cell prolymphocytic leukemia 17 trials
- Aggressive NK-cell leukemia 11 trials
- Breast implant-associated anaplastic large cell lymphoma 3 trials
- Hydroa vacciniforme-like lymphoma 3 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
Primary cutaneous T-cell lymphoma 4 trials · 92 incl. sub-types
4 sub-types
-
T-lymphoblastic lymphoma 32 trials
-
CD4+/CD56+ hematodermic neoplasm 31 trials
-
Adult T-cell leukemia/lymphoma 31 trials
-
Enteropathy-associated T-cell lymphoma 20 trials
1 sub-type
-
Hepatosplenic T-cell lymphoma 16 trials
Most studied deeper sub-types
-
Lymphoma drug duvelisib tested after transplant – trial ends early
Disease control Stopped earlyThis phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full resul…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Early trial of tazemetostat for tough T-Cell lymphoma halted after just 6 patients
Disease control Stopped earlyThis early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy combo after transplant shows promise for High-Risk blood cancers
Disease control Stopped earlyThis study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control Stopped earlyThis early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…
Phase 1/2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot for tough lymphomas shows early promise but trial halted
Disease control Stopped earlyThis early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC